EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
-12.53%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$2.88B
AUM Growth
+$2.88B
(-10%)
Cap. Flow
+$229M
Cap. Flow
% of AUM
7.97%
Top 10 Holdings %
Top 10 Hldgs %
61.04%
Holding
99
New
12
Increased
15
Reduced
4
Closed
20
Top Buys
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$178M |
| 2 |
Arvinas
ARVN
|
$68.2M |
| 3 |
Sarepta Therapeutics
SRPT
|
$59.9M |
| 4 |
Revolution Medicines
RVMD
|
$58.5M |
| 5 |
Allogene Therapeutics
ALLO
|
$51.2M |
Top Sells
| 1 |
Arcus Biosciences
RCUS
|
$103M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$41.2M |
| 3 |
Vaxcyte
PCVX
|
$31.5M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
$24M |
| 5 |
Exelixis
EXEL
|
$21.6M |
Sector Composition
| 1 | Healthcare | 99.13% |
| 2 | Financials | 0.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$441M
| $315M | 10.86% | 11,584,280 | – | – |
|
2
Apellis Pharmaceuticals
APLS
$3.48B
| $234M | 8.09% | 5,183,431 | – | – |
|
|
3
Sarepta Therapeutics
SRPT
$1.78B
| $215M | 7.42% | 2,868,145 +798,511 | +39% | +$59.9M |
|
|
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
| $178M | 6.16% | +1,008,628 | New | +$178M |
|
5
Galapagos
GLPG
$2.07B
| $178M | 6.16% | 3,197,500 +1,876 | +0.1% | +$105K |
|
6
AnaptysBio
ANAB
$569M
| $153M | 5.27% | 7,521,024 | – | – |
|
7
Xencor
XNCR
$580M
| $145M | 4.99% | 5,282,416 +313,660 | +6% | +$8.58M |
|
|
8
Arvinas
ARVN
$568M
| $131M | 4.54% | 3,123,300 +1,619,371 | +108% | +$68.2M |
|
9
Kura Oncology
KURA
$686M
| $122M | 4.2% | 6,638,371 | – | – |
|
|
MORF
10
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $85.7M | 2.96% | 3,951,566 | – | – |
|
11
Acadia Pharmaceuticals
ACAD
$4.38B
| $84.4M | 2.91% | 5,991,479 | – | – |
|
12
Zai Lab
ZLAB
$3.68B
| $84.3M | 2.91% | 2,431,885 +208,673 | +9% | +$7.24M |
|
|
13
Revolution Medicines
RVMD
$7.1B
| $83.4M | 2.88% | 4,278,069 +3,003,972 | +236% | +$58.5M |
|
14
Relay Therapeutics
RLAY
$619M
| $62.4M | 2.15% | 3,723,541 +1,432,100 | +62% | +$24M |
|
|
RETA
15
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $60M | 2.07% | 1,975,611 | – | – |
|
|
16
Allogene Therapeutics
ALLO
$251M
| $51.2M | 1.77% | +4,488,200 | New | +$51.2M |
|
17
argenx
ARGX
$43.6B
| $47.4M | 1.63% | 125,000 | – | – |
|
|
TSVT
18
DELISTED
2seventy bio
TSVT
| $46.1M | 1.59% | 3,495,943 | – | – |
|
19
Nuvation Bio
NUVB
$1.02B
| $45M | 1.55% | 13,896,543 | – | – |
|
20
Atea Pharmaceuticals
AVIR
$267M
| $45M | 1.55% | 6,340,639 | – | – |
|
|
CERE
21
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $43.5M | 1.5% | 1,646,260 | – | – |
|
22
Alector
ALEC
$238M
| $41.2M | 1.42% | 4,056,548 -1,681,900 | -29% | -$17.1M |
|
23
Avidity Biosciences
RNA
$5.99B
| $40.1M | 1.38% | 2,759,505 | – | – |
|
24
Design Therapeutics
DSGN
$315M
| $36.9M | 1.27% | 2,634,178 +262,733 | +11% | +$3.68M |
|
25
Voyager Therapeutics
VYGR
$186M
| $28.1M | 0.97% | 4,753,907 +1,196,400 | +34% | +$7.07M |
|